Abstract
A double-blind randomized comparison (protocol S3AB4003, Glaxo Wellcome, Great Britain) carried out in a group of 52 children showed that the 5-HT3-receptor antagonist ondansetron (in syrup) effectively prevented vomiting, nausea and loss of appetite caused in combination chemotherapy with highly- or moderately emetogenic cytostatic drugs in 92.3; 69.3 and 81.0%, respectively. Treatment was given to patients who were on dexamethasone. With intravenous injection of ondansetron plus dexamethasone, per os, said indices were 88.5; 73.2%; 73.2%, respectively, thus showing no significant differences. No side-effects were observed with either regimen.
Publication types
-
Clinical Trial
-
English Abstract
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Administration, Oral
-
Antiemetics / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Child
-
Child, Preschool
-
Double-Blind Method
-
Humans
-
Infusions, Intravenous
-
Nausea / chemically induced
-
Nausea / prevention & control*
-
Neoplasms / drug therapy*
-
Ondansetron / administration & dosage*
-
Serotonin Antagonists / administration & dosage*
-
Treatment Outcome
-
Vomiting / chemically induced
-
Vomiting / prevention & control*
Substances
-
Antiemetics
-
Serotonin Antagonists
-
Ondansetron